Form 4: Pfizer Executive Christoffel Boshoff Reports Changes in Beneficial Ownership

Christoffel Boshoff, President of R&D at Pfizer, reports acquisition and disposal of common stock related to performance share awards.

Summary

• On February 26, 2025, Christoffel Boshoff, President of R&D at Pfizer Inc., reported changes in beneficial ownership of Pfizer's common stock.
• Boshoff acquired 9,687 shares of common stock due to the earn-out of performance share awards.
• Simultaneously, 4,872 shares were disposed of to satisfy tax obligations related to the earn-out.
• Following these transactions, Boshoff directly owns 155,100 shares of Pfizer common stock and indirectly owns 664 shares through a Rule 16b-3 plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing reflecting compensation-related transactions. The acquisition of shares due to performance awards is mildly positive, but the disposal for tax obligations is a standard procedure.

Positives

• The acquisition of shares reflects the achievement of performance targets, which can be seen as a positive indicator of Boshoff's performance and the company's progress in R&D.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in company stock. It's a standard practice across publicly traded companies.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates